Immune checkpoint inhibitors (ICIs) have become a pillar of cancer therapy. The cardiovascular complications of ICIs extend beyond myocarditis and can involve any component of the cardiovascular system, including the pericardium, coronary arteries and conduction system. Clinicians caring for patients treated with ICIs must be vigilant for the cardiovascular complications of these therapies, which might portend a poor prognosis.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Haslam, A., Gill, J. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw. Open 3, e200423 (2020).
D’Souza, M. et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur. Heart J. 42, 1621–1631 (2021).
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755–1764 (2018).
Ball, S. et al. Cardiovascular toxicities of immune checkpoint inhibitors. J. Am. Coll. Cardiol. 74, 1714–1727 (2019).
Won, T. et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 41, 111611 (2022).
Gong, J. et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J. Immunother. Cancer 9, e002771 (2021).
Vuong, J. T. et al. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications. J. Am. Coll. Cardiol. 79, 577–593 (2022).
Drobni, Z. D. et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142, 2299–2311 (2020).
T.G.N. has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CRO Oncology, Genentech, H3 Biomedicine, Roche and Sanofi, and has received grant funding from AstraZeneca and Bristol Myers Squibb for work related to the cardiovascular complications of immune checkpoint inhibitors. K.J. declares no competing interests.
Rights and permissions
About this article
Cite this article
Josan, K., Neilan, T.G. Immune checkpoint inhibitors: acute and chronic cardiovascular complications. Nat Rev Cardiol 20, 73–74 (2023). https://doi.org/10.1038/s41569-022-00827-1